+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Tirofiban"

Angina (Angina Pectoris) - Pipeline Review, H2 2020 - Product Thumbnail Image

Angina (Angina Pectoris) - Pipeline Review, H2 2020

  • Drug Pipelines
  • October 2020
  • 89 Pages
  • Global
From
Angina (Angina Pectoris) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update - Product Thumbnail Image

Angina (Angina Pectoris) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • Report
  • July 2022
  • 63 Pages
  • Global
From
Medicinal Chemistry of Drugs Affecting Cardiovascular and Endocrine Systems - Product Thumbnail Image

Medicinal Chemistry of Drugs Affecting Cardiovascular and Endocrine Systems

  • Book
  • February 2024
  • 3 Results (Page 1 of 1)
Loading Indicator

Tirofiban is a cardiovascular drug used to treat acute coronary syndrome (ACS). It is a glycoprotein IIb/IIIa inhibitor, which works by blocking the action of platelets in the blood, preventing them from forming clots. Tirofiban is administered intravenously and is used in combination with other drugs to reduce the risk of death and heart attack in patients with ACS. It is also used to reduce the risk of stroke in patients with non-ST-segment elevation myocardial infarction (NSTEMI). Tirofiban is available in both generic and branded forms, and is marketed by several pharmaceutical companies. Some of the companies in the market include Merck, Sanofi, Pfizer, Bristol-Myers Squibb, and AstraZeneca. Show Less Read more